{"id":11127,"date":"2013-07-31T00:00:00","date_gmt":"2013-07-30T22:00:00","guid":{"rendered":"https:\/\/idibell.cat\/es\/blog\/2013\/07\/31\/patentan-una-molecula-que-abre-la-puerta-a-desarrollar-nuevos-farmacos-contra-el-rechazo-inmunitario\/"},"modified":"2021-11-18T12:00:53","modified_gmt":"2021-11-18T11:00:53","slug":"patentan-una-molecula-que-abre-la-puerta-a-desarrollar-nuevos-farmacos-contra-el-rechazo-inmunitario","status":"publish","type":"post","link":"https:\/\/idibell.cat\/es\/2013\/07\/patentan-una-molecula-que-abre-la-puerta-a-desarrollar-nuevos-farmacos-contra-el-rechazo-inmunitario\/","title":{"rendered":"Patentan una mol\u00e9cula que abre la puerta a desarrollar nuevos f\u00e1rmacos contra el rechazo inmunitario"},"content":{"rendered":"

Investigadores del grupo de investigaci\u00f3n en Gen\u00e9tica Molecular Humana del Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL), liderados por la investigadora Mercedes P\u00e9rez, han patentado un p\u00e9ptido (mol\u00e9cula formada por una secuencia de amino\u00e1cidos) que inhibe la respuesta inmunitaria activada por la enzima calcineurina que podr\u00eda servir para desarrollar nuevos f\u00e1rmacos inmunosupresores m\u00e1s espec\u00edficos y con menos efectos secundarios que los actuales.<\/p>\n

Los resultados del estudio que describe este mecanismo molecular se han publicado en la revista Mollecular Cell Research.<\/p>\n

F\u00e1rmacos actuales<\/strong>
\nLos pacientes sometidos a un trasplante necesitan a d\u00eda de hoy un tratamiento de por vida que detenga la respuesta inmunitaria generada por el rechazo de su cuerpo a un organismo extra\u00f1o. Los f\u00e1rmacos que se utilizan actualmente, la ciclosporina A y el FK506, inhiben la calcineurina, que es la enzima que activa la respuesta inmunitaria. El problema es que su mecanismo de acci\u00f3n hace que se detengan todas las dem\u00e1s v\u00edas que activa esta enzima provocando numerosos efectos secundarios. \u00abEl objetivo de la investigaci\u00f3n\u00bb, explic\u00f3 la investigadora Mercedes P\u00e9rez, \u00abes desarrollar nuevos f\u00e1rmacos m\u00e1s espec\u00edficos, que inhiban \u00fanicamente la respuesta inmunitaria activada por la calcineurina y no todas sus otras funciones\u00bb.<\/p>\n

En estudios anteriores, el equipo de P\u00e9rez ya hab\u00eda descrito un p\u00e9ptido de la familia de prote\u00ednas RCAN capaz de unirse a la calcineurina e inhibir de forma espec\u00edfica la activaci\u00f3n de la respuesta inmunitaria. En este trabajo los investigadores del IDIBELL han modificado este p\u00e9ptido y descubierto que adem\u00e1s, cuando este p\u00e9ptido est\u00e1 fosforilado por la prote\u00edna CK2 (la fosforilaci\u00f3n es un mecanismo de regulaci\u00f3n de las prote\u00ednas que consiste en la adici\u00f3n de un grupo fosfato) aumenta su poder inmunosupresor.<\/p>\n

\u00abHemos patentado este p\u00e9ptido fosforilado que adem\u00e1s de su potencial como inmunosupresor nos permitir\u00e1 buscar mol\u00e9culas mim\u00e9ticas, que hagan la misma funci\u00f3n pero sean m\u00e1s estables, lo que nos permitir\u00e1 poder trasladar a la cl\u00ednica\u00bb explic\u00f3 la investigadora.<\/p>\n

El estudio se ha realizado en colaboraci\u00f3n con la Universidad de Barcelona, \u200b\u200bla Universidad Aut\u00f3noma de Barcelona y el Parque de Investigaci\u00f3n Biom\u00e9dica de Barcelona (PRBB).<\/p>\n

 <\/p>\n

Referencia del art\u00edculo<\/strong>
\nMart\u00ednez-Hoyer S., Aranguren-Ib\u00e1\u00f1ez A., Garc\u00eda-Garc\u00eda J., Serrano_candelas E., Vilardell J., Nunes V., Aguado F., Oliva B., Itarte E. and P\u00e9rez-Riba M.Protein kinase CK2-depdendent phosphorylation of the human regulators of calcineurin reveals a novel mechanism regulating the calcineurin-NFATc signaling pathwa<\/span>y<\/a>. Molecular Cell Research 1833 (2013) 2311-2321.<\/p>\n","protected":false},"excerpt":{"rendered":"

Investigadores del grupo de investigaci\u00f3n en Gen\u00e9tica Molecular Humana del Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL), liderados por la investigadora Mercedes P\u00e9rez, han patentado un p\u00e9ptido (mol\u00e9cula formada por una secuencia de amino\u00e1cidos) que inhibe la respuesta inmunitaria activada por la enzima calcineurina que podr\u00eda servir para desarrollar nuevos f\u00e1rmacos inmunosupresores m\u00e1s espec\u00edficos y […]<\/p>\n","protected":false},"author":6,"featured_media":19081,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[186,305,297],"tags":[275],"class_list":["post-11127","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-area-medicina-traslacional","category-genetica-molecular-humana-programa-de-genes-enfermedad-y-terapia","category-programa-de-genes-enfermedad-y-terapia","tag-medicina-traslacional"],"publishpress_future_action":{"enabled":false,"date":"2024-12-25 21:24:02","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/11127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/comments?post=11127"}],"version-history":[{"count":3,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/11127\/revisions"}],"predecessor-version":[{"id":19082,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/11127\/revisions\/19082"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media\/19081"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media?parent=11127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/categories?post=11127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/tags?post=11127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}